Fakülteler / Faculties
Permanent URI for this communityhttps://hdl.handle.net/11727/1395
Browse
41 results
Search Results
Item Comment on: Intensity Modulated Radiotherapy in Head and Neck Cancer: Initial Experience of the First Treated Cases from North-East India(2023) Topkan, Erkan; Somay, Efsun; Selek, Ugur; 0000-0001-8251-6913; 38187854; AAG-2213-2021; O-5474-2014Item Letter to the Editor Regarding "Long-Term Swallow Outcomes and Factors Affecting Swallowing Dysfunction and Quality of Life Among Oral Cancer Patients: A Prospective Observational Study" by Thaduri Et Al. Eur Arch Otorhinolaryngol. 2023 Aug 7. Doi: 10.1007/S00405-023-08155-X(2023) Topkan, Erkan; Somay, Efsun; Selek, Ugur; 37594546; O-5474-2014; AAG-2213-2021Item Comment on: Quality of Life After Segmental Mandibulectomy and Free Flap for Mandibular Osteonecrosis: Systematic Review(2023) Topkan, Erkan; Somay, Efsun; 0000-0001-8251-6913; 37459741; AAG-2213-2021Item Radiation Therapy for Ct1-2 Carcinoma of the Palatine Tonsil Diagnosed Via A Simple Tonsillectomy: Dosimetry and Patterns of Care in the IMRT Era(2023) Topkan, Erkan; Somay, Efsun; Yilmaz, Busra; 0000-0001-8120-7123; 37804565; AAG-2213-2021Item Response to Outcomes of Immediate Dental Implants in Vascularised Bone Flaps for Mandibular Reconstruction(2023) Somay, Efsun; Topkan, Erkan; 0000-0001-8120-7123; 0000-0001-8251-6913; 37565638; AAG-2213-2021Item Letter to the Editor Regarding "Radiologic Findings of Osteonecrosis, Osteoradionecrosis, Osteomyelitis and Jaw Metastatic Disease with Cone Beam CT"(2023) Yilmaz, Busra; Topkan, Erkan; 0000-0001-8120-7123; 37806191; AAG-2213-2021Item Predictive Value of Health-Related Quality of Life on Radiotherapy-Related Toxicities in Patients with Head and Neck Cancer(2023) Somay, Efsun; Topkan, Erkan; Selek, Ugur; 0000-0001-8120-7123; 0000-0001-8087-3140; 0000-0001-8251-6913; 37874385; AAG-2213-2021; O-5474-2014Item Letter to The Editor: To Extract or Not Extract Teeth Prior to Head and Neck Radiotherapy?(2023) Yilmaz, Busra; Somay, Efsun; Topkan, Erkan; https://orcid.org/0000-0003-0633-5648; https://orcid.org/0000-0001-8251-6913; https://orcid.org/0000-0001-8120-7123; 36576606; AAR-6904-2020; AAG-2213-2021Item Definitive Chemoradiation Therapy Following Surgical Resection or Radiosurgery Plus Whole-Brain Radiation Therapy in Non-Small Cell Lung Cancer Patients With Synchronous Solitary Brain Metastasis: A Curative Approach(2014) Parlak, Cem; Mertsoylu, Huseyin; Guler, Ozan Cem; Onal, Cem; Topkan, Erkan; https://orcid.org/0000-0001-6170-0383; https://orcid.org/0000-0002-1932-9784; https://orcid.org/0000-0001-6908-3412; https://orcid.org/0000-0002-2742-9021; https://orcid.org/0000-0001-8120-7123; 24495594; B-3671-2014; M-9530-2014; AAC-5654-2020; HOC-5611-2023; AAG-2213-2021Purpose/Objectives: The aim of this study was to evaluate the impact of definitive thoracic chemoradiation therapy following surgery or stereotactic radiosurgery (SRS) and whole-brain radiation therapy (WBRT) on the outcomes of patients with non-small cell lung cancer (NSCLC) with synchronous solitary brain metastasis (SSBM). Methods and Materials: A total of 63 NSCLC patients with SSBM were retrospectively evaluated. Patients were staged using positron emission tomography-computed tomography in addition to conventional staging tools. Thoracic radiation therapy (TRT) with a total dose of 66 Gy in 2 Gy fractions was delivered along with 2 cycles of cisplatin-based chemotherapy following either surgery plus 30 Gy of WBRT (n = 33) or SRS plus 30 Gy of WBRT (n = 30) for BM. Results: Overall, the treatment was well tolerated. All patients received planned TRT, and 57 patients (90.5%) were also able to receive 2 cycles of chemotherapy. At a median follow-up of 25.3 months (7.1-52.1 months), the median months of overall, locoregional progression-free, neurological progression-free, and progression-free survival were 28.6, 17.7, 26.4, and 14.6, respectively. Both univariate and multivariate analyses revealed that patients with a T1-T2 thoracic disease burden (P = .001), a nodal stage of N0-N1 (P = .003), and no weight loss (P = .008) exhibited superior survival. Conclusions: In the present series, surgical and radiosurgical treatments directed toward SSBM in NSCLC patients were equally effective. The similarities between the present survival outcomes and those reported in other studies for locally advanced NSCLC patients indicate the potentially curative role of definitive chemoradiation therapy for highly selected patients with SSBM. (C) 2014 Elsevier Inc.Item Safety and Palliative Efficacy of Single-Dose 8-Gy Reirradiation for Painful Local Failure in Patients with Stage IV Non-Small Cell Lung Cancer Previously Treated with Radical Chemoradiation Therapy(2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozan Cem; Parlak, Cem; Pehlivan, Berrin; Selek, Ugur; 0000-0001-8120-7123; 0000-0001-6170-0383; 0000-0001-6661-4185; 0000-0001-6908-3412; 0000-0001-8087-3140; 25752391; AAG-2213-2021; B-3671-2014; V-5717-2017; AAC-5654-2020; O-5474-2014Purpose: To investigate the safety and efficacy of single-dose 8-Gy palliative chest reirradiation (CRI) in metastatic non-small cell lung cancer (M-NSCLC) patients with painful thoracic failures (TF) within the previous radiation portal. Patients and Methods: We retrospectively analyzed the clinical data of 78 M-NSCLC patients who received single-dose 8-Gy CRI for painful TF after concurrent chemoradiation therapy to a total radiation dose of 52 to 66 Gy between 2007 and 2012. Primary endpoints included significant pain relief (SPR) defined as a >= 2 point decrement in the Visual Analogue Scale for Pain inventory (VAS-P), time to pain relief, and duration of pain control. Secondary objectives were survival and prognostic factors. Results: Treatment was well tolerated, with only 5.1% grade 3 pneumonitis and 1.3% grade 2 esophagitis. Pre-CRI median and post-CRI minimum VAS-P were 7 and 3 (P < .001), respectively. SPR was noted in 67 (85.9%) patients, and only 3 (3.9%) scored progressive pain. Median time to lowest VAS-P and duration of pain control were 27 days and 6.1 months, respectively. Median overall survival (OS) was 7.7 months, and the 1-year OS rate was 26.5%. On multivariate analyses, lower Eastern Cooperative Oncology group score (1-2; P < .001), absence of anemia (P = .001), and fewer metastatic sites (1-2; P < .001) were found to be associated with longer OS. Conclusions: Single-dose 8-Gy CRI provides safe, effective, and durable pain palliation for TF in radically irradiated M-NSCLC patients. Because of its convenience, lower cost, and higher comfort, the present protocol can be considered an appropriate option for patients with limited life spans. (C) 2015 Elsevier Inc.